Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report
Authors:
- Luiz Euribel Prestes-CarneiroLuiz Euribel Prestes-Carneiro
- Marilda Aparecida Milanez Morgado de AbreuMAMarilda Aparecida Milanez Morgado de Abreu
- Eduardo Vinicius Mendes RoncadaEREduardo Vinicius Mendes Roncada
- Diego Garcia MuchonDMDiego Garcia Muchon
- Fernanda Miranda CalianiFCFernanda Miranda Caliani
- Dewton Moraes VasconcelosDVDewton Moraes Vasconcelos
Open Access
Abstract
A 35-year-old man with a late-onset combined immunodeficiency (LOCID) variant of common variable immunodeficiency, severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease was attended in the Regional Hospital of Presidente Prudente and HC-FMUSP, São Paulo, Brazil. Anti-IL-12/IL-23 (ustekinumab) monoclonal antibody was prescribed due to the failure of other treatments (phototherapy, oral acitretin) for psoriasis and a Psoriasis Area Severity Index >10. We evaluated the impact of treatment with ustekinumab on severe infectious diseases in a patient with uncontrolled psoriasis and LOCID followed for 8 years. Four quarterly doses of ustekinumab 90 mg and human immunoglobulin replacement (10,000 mg at 28-day intervals) were administered. Immunophenotyping, cultures of lymphocytes, genetic sequencing, and whole exome sequencing were performed to investigate the primary immunodeficiency. Normal lymphocyte proliferation; pathogenic variants in genetic sequencing, and clinically significant variants in the whole exome for primary immunodeficiencies were not detected. The main infections before and after treatment with ustekinumab were chronic sinusitis and gastroenteritis. The patient was infected with COVID-19, dengue (twice) and influenza and was hospitalized three times for intravenous antibiotic therapy. Ustekinumab did not influence the susceptibility of the patient with LOCID to severe infections and significantly improved psoriasis, psoriatic arthritis, and Crohn’s disease.Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- StatPearls2020
- High-Dose Intravenous Immunoglobulin in Skin Autoimmune DiseaseFrontiers in Immunology, 2019
- Early real-world effectiveness of ustekinumab for Crohn’s diseaseFrontline Gastroenterology, 2019
- Primary immunodeficiencyAllergy, Asthma & Clinical Immunology, 2018
- Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the EvidenceDrugs in R&D, 2017
- Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasisHuman Vaccines & Immunotherapeutics, 2017
- Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumabThe Journal of Dermatology, 2017
- Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM RegistryJournal of Investigative Dermatology, 2017
- Skin Manifestations of Primary Immune DeficiencyClinical Reviews in Allergy & Immunology, 2013
- Autoimmunity, autoinflammation and lymphoma in combined immunodeficiency (CID)Autoimmunity Reviews, 2010